{"id":754742,"date":"2023-05-04T07:32:42","date_gmt":"2023-05-04T11:32:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\/"},"modified":"2023-05-04T07:32:42","modified_gmt":"2023-05-04T11:32:42","slug":"rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\/","title":{"rendered":"RVL Pharmaceuticals plc to Discuss First Quarter 2023 Financial Results and Provide Commercial Update"},"content":{"rendered":"<h2>\nConference call to be held Thursday, May 11, 2023, at 8:30 a.m. ET<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>BRIDGEWATER, N.J., May  04, 2023  (GLOBE NEWSWIRE) &#8212; RVL Pharmaceuticals plc (Nasdaq: RVLP) (\u201cRVL\u201d or the \u201cCompany\u201d), a specialty pharmaceutical company focused on the commercialization of UPNEEQ<sup>\u00ae<\/sup> (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today announced that the Company will release its first quarter 2023 financial results and provide a commercial update on Thursday, May 11, 2023, before U.S. financial markets open.<\/p>\n<p align=\"justify\">Brian Markison, Chief Executive Officer, James \u201cJD\u201d Schaub, Chief Operating Officer, and Mike DePetris, Principal Accounting Officer, will host a conference call as follows:<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:25%;width:25%;min-width:25%\">Date<\/td>\n<td style=\"max-width:75%;width:75%;min-width:75%\">Thursday, May 11, 2023<\/td>\n<\/tr>\n<tr>\n<td>Time\u00a0<\/td>\n<td>8:30 a.m. ET<\/td>\n<\/tr>\n<tr>\n<td>Toll free (U.S.)<\/td>\n<td>800-579-2543<\/td>\n<\/tr>\n<tr>\n<td>International\u00a0<\/td>\n<td>785-424-1789<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>Webcast (live and replay)<\/td>\n<td>ir.rvlpharma.com under the \u201cInvestors &amp; News\u201d section<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <strong>IMPORTANT SAFETY INFORMATION<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>INDICATION<\/strong>\n      <\/p>\n<p align=\"justify\">UPNEEQ<sup>\u00ae<\/sup> (oxymetazoline hydrochloride ophthalmic solution), 0.1% is indicated for the treatment of acquired blepharoptosis in adults.<\/p>\n<p align=\"justify\">\n        <strong>WARNINGS AND PRECAUTIONS<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:10pt;text-align:justify\">Ptosis may be associated with neurologic or orbital diseases such as stroke and\/or cerebral aneurysm, Horner syndrome, myasthenia gravis, external ophthalmoplegia, orbital infection and orbital masses. Consideration should be given to these conditions in the presence of ptosis with decreased levator muscle function and\/or other neurologic signs.<\/li>\n<li style=\"margin-bottom:10pt;text-align:justify\">Alpha-adrenergic agonists as a class may impact blood pressure. Advise UPNEEQ patients with cardiovascular disease, orthostatic hypotension, and\/or uncontrolled hypertension or hypotension to seek medical care if their condition worsens.<\/li>\n<li style=\"margin-bottom:10pt;text-align:justify\">Use UPNEEQ with caution in patients with cerebral or coronary insufficiency or Sj\u00f6gren\u2019s syndrome. Advise patients to seek medical care if signs and symptoms of potentiation of vascular insufficiency develop.<\/li>\n<li style=\"margin-bottom:10pt;text-align:justify\">UPNEEQ may increase the risk of angle closure glaucoma in patients with untreated narrow-angle glaucoma. Advise patients to seek immediate medical care if signs and symptoms of acute narrow-angle glaucoma develop.<\/li>\n<li style=\"margin-bottom:10pt;text-align:justify\">Patients should not touch the tip of the single patient-use container to their eye or to any surface, in order to avoid eye injury or contamination of the solution.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>ADVERSE REACTIONS<\/strong>\n      <\/p>\n<p align=\"justify\">Adverse reactions that occurred in 1-5% of subjects treated with UPNEEQ were punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, eye irritation and headache.<\/p>\n<p><strong>DRUG INTERACTIONS<\/strong><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:10pt;text-align:justify\">Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as betablockers, anti-hypertensives, and\/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy.<\/li>\n<li style=\"margin-bottom:10pt;text-align:justify\">Caution is advised in patients taking monoamine oxidase inhibitors which can affect the metabolism and uptake of circulating amines.<\/li>\n<\/ul>\n<p>\n        <strong>About RVL Pharmaceuticals plc<\/strong>\n      <\/p>\n<p align=\"justify\">RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization of UPNEEQ<sup>\u00ae<\/sup> (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.<\/p>\n<p>\n        <strong>Investor and Media Relations for RVL Pharmaceuticals plc<\/strong>\n      <\/p>\n<p>Lisa M. Wilson<br \/>In-Site Communications, Inc.<br \/>T: 212-452-2793<br \/>E: lwilson@insitecony.com<\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDEwNiM1NTcwMDA2IzIwOTc4Nzk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MWFmYjllNzQtNTQzOC00ODlkLTliMzEtMjZhYTZiMmU4NDU4LTExMDk0NTA=\/tiny\/RVL-Pharmaceuticals-plc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Conference call to be held Thursday, May 11, 2023, at 8:30 a.m. ET BRIDGEWATER, N.J., May 04, 2023 (GLOBE NEWSWIRE) &#8212; RVL Pharmaceuticals plc (Nasdaq: RVLP) (\u201cRVL\u201d or the \u201cCompany\u201d), a specialty pharmaceutical company focused on the commercialization of UPNEEQ\u00ae (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today announced that the Company will release its first quarter 2023 financial results and provide a commercial update on Thursday, May 11, 2023, before U.S. financial markets open. Brian Markison, Chief Executive Officer, James \u201cJD\u201d Schaub, Chief Operating Officer, and Mike DePetris, Principal Accounting Officer, will host a conference call as follows: Date Thursday, May 11, 2023 Time\u00a0 8:30 a.m. ET Toll free (U.S.) 800-579-2543 International\u00a0 785-424-1789 \u00a0 \u00a0 Webcast (live and replay) ir.rvlpharma.com under &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;RVL Pharmaceuticals plc to Discuss First Quarter 2023 Financial Results and Provide Commercial Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-754742","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>RVL Pharmaceuticals plc to Discuss First Quarter 2023 Financial Results and Provide Commercial Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RVL Pharmaceuticals plc to Discuss First Quarter 2023 Financial Results and Provide Commercial Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Conference call to be held Thursday, May 11, 2023, at 8:30 a.m. ET BRIDGEWATER, N.J., May 04, 2023 (GLOBE NEWSWIRE) &#8212; RVL Pharmaceuticals plc (Nasdaq: RVLP) (\u201cRVL\u201d or the \u201cCompany\u201d), a specialty pharmaceutical company focused on the commercialization of UPNEEQ\u00ae (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today announced that the Company will release its first quarter 2023 financial results and provide a commercial update on Thursday, May 11, 2023, before U.S. financial markets open. Brian Markison, Chief Executive Officer, James \u201cJD\u201d Schaub, Chief Operating Officer, and Mike DePetris, Principal Accounting Officer, will host a conference call as follows: Date Thursday, May 11, 2023 Time\u00a0 8:30 a.m. ET Toll free (U.S.) 800-579-2543 International\u00a0 785-424-1789 \u00a0 \u00a0 Webcast (live and replay) ir.rvlpharma.com under &hellip; Continue reading &quot;RVL Pharmaceuticals plc to Discuss First Quarter 2023 Financial Results and Provide Commercial Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-04T11:32:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDEwNiM1NTcwMDA2IzIwOTc4Nzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"RVL Pharmaceuticals plc to Discuss First Quarter 2023 Financial Results and Provide Commercial Update\",\"datePublished\":\"2023-05-04T11:32:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\\\/\"},\"wordCount\":491,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMDEwNiM1NTcwMDA2IzIwOTc4Nzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\\\/\",\"name\":\"RVL Pharmaceuticals plc to Discuss First Quarter 2023 Financial Results and Provide Commercial Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMDEwNiM1NTcwMDA2IzIwOTc4Nzk=\",\"datePublished\":\"2023-05-04T11:32:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMDEwNiM1NTcwMDA2IzIwOTc4Nzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMDEwNiM1NTcwMDA2IzIwOTc4Nzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RVL Pharmaceuticals plc to Discuss First Quarter 2023 Financial Results and Provide Commercial Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RVL Pharmaceuticals plc to Discuss First Quarter 2023 Financial Results and Provide Commercial Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\/","og_locale":"en_US","og_type":"article","og_title":"RVL Pharmaceuticals plc to Discuss First Quarter 2023 Financial Results and Provide Commercial Update - Market Newsdesk","og_description":"Conference call to be held Thursday, May 11, 2023, at 8:30 a.m. ET BRIDGEWATER, N.J., May 04, 2023 (GLOBE NEWSWIRE) &#8212; RVL Pharmaceuticals plc (Nasdaq: RVLP) (\u201cRVL\u201d or the \u201cCompany\u201d), a specialty pharmaceutical company focused on the commercialization of UPNEEQ\u00ae (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today announced that the Company will release its first quarter 2023 financial results and provide a commercial update on Thursday, May 11, 2023, before U.S. financial markets open. Brian Markison, Chief Executive Officer, James \u201cJD\u201d Schaub, Chief Operating Officer, and Mike DePetris, Principal Accounting Officer, will host a conference call as follows: Date Thursday, May 11, 2023 Time\u00a0 8:30 a.m. ET Toll free (U.S.) 800-579-2543 International\u00a0 785-424-1789 \u00a0 \u00a0 Webcast (live and replay) ir.rvlpharma.com under &hellip; Continue reading \"RVL Pharmaceuticals plc to Discuss First Quarter 2023 Financial Results and Provide Commercial Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-04T11:32:42+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDEwNiM1NTcwMDA2IzIwOTc4Nzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"RVL Pharmaceuticals plc to Discuss First Quarter 2023 Financial Results and Provide Commercial Update","datePublished":"2023-05-04T11:32:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\/"},"wordCount":491,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDEwNiM1NTcwMDA2IzIwOTc4Nzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\/","name":"RVL Pharmaceuticals plc to Discuss First Quarter 2023 Financial Results and Provide Commercial Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDEwNiM1NTcwMDA2IzIwOTc4Nzk=","datePublished":"2023-05-04T11:32:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDEwNiM1NTcwMDA2IzIwOTc4Nzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMDEwNiM1NTcwMDA2IzIwOTc4Nzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rvl-pharmaceuticals-plc-to-discuss-first-quarter-2023-financial-results-and-provide-commercial-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"RVL Pharmaceuticals plc to Discuss First Quarter 2023 Financial Results and Provide Commercial Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754742","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=754742"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754742\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=754742"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=754742"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=754742"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}